ARTICLE | Clinical News
Betmiga mirabegron regulatory update
July 1, 2013 7:00 AM UTC
The U.K.'s NICE issued final guidance recommending Betmiga mirabegron from Astellas for the symptomatic treatment of overactive bladder (OAB) only in patients for whom antimuscarinic drugs are not sui...